GT Biopharma (GTBP) Competitors

Passage Bio (NASDAQ:PASG) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.

Do analysts recommend PASG or GTBP?

Passage Bio presently has a consensus target price of $7.50, suggesting a potential upside of 1,818.16%. GT Biopharma has a consensus target price of $11.00, suggesting a potential upside of 287.32%. Given Passage Bio's higher possible upside, research analysts clearly believe Passage Bio is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
GT Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Is PASG or GTBP more profitable?

Passage Bio's return on equity of -72.53% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-72.53%	-52.10%
GT Biopharma	N/A	-257.47%	-131.09%

Does the MarketBeat Community prefer PASG or GTBP?

GT Biopharma received 64 more outperform votes than Passage Bio when rated by MarketBeat users. However, 68.83% of users gave Passage Bio an outperform vote while only 63.24% of users gave GT Biopharma an outperform vote.

Company	Underperform	Outperform
Passage Bio	Outperform Votes 53 68.83%	Underperform Votes 24 31.17%
GT Biopharma	Outperform Votes 117 63.24%	Underperform Votes 68 36.76%

Which has more risk and volatility, PASG or GTBP?

Passage Bio has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of PASG or GTBP?

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 8.1% of GT Biopharma shares are owned by institutional investors. 5.0% of Passage Bio shares are owned by insiders. Comparatively, 10.9% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has preferable valuation and earnings, PASG or GTBP?

GT Biopharma is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$102.06M	-$1.02	-0.38
GT Biopharma	N/A	N/A	-$7.60M	-$5.69	-0.50

Does the media prefer PASG or GTBP?

In the previous week, GT Biopharma had 2 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for GT Biopharma and 1 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.87 beat GT Biopharma's score of 0.46 indicating that Passage Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Passage Bio	Very Positive
GT Biopharma	Neutral

Summary

Passage Bio beats GT Biopharma on 10 of the 16 factors compared between the two stocks.